LIVIVO - Search results -

Search results

Result 1 - 10 of total 23

Search options

Article ; Online: Defining the Role of the miR-145-KLF4-αSMA Axis in Mitral Valvular Interstitial Cell Activation in Myxomatous Mitral Valve Prolapse Using the Canine Model.

Yang, Vicky K / Moyer, Nicole / Zhou, Runzi / Carnevale, Sally Z / Meola, Dawn M / Robinson, Sally R / Li, Guoping / Das, Saumya

International journal of molecular sciences

2024 Volume 25, Issue 3

Abstract: Mitral valve prolapse (MVP) is a common valvular disease, affecting 2-3% of the adult human population and is a degenerative condition. A total of 5-10% of the afflicted will develop severe mitral regurgitation, cardiac dysfunction, congestive heart ... ...

Abstract	Mitral valve prolapse (MVP) is a common valvular disease, affecting 2-3% of the adult human population and is a degenerative condition. A total of 5-10% of the afflicted will develop severe mitral regurgitation, cardiac dysfunction, congestive heart failure, and sudden cardiac death. Naturally occurring myxomatous MVP in dogs closely resembles MVP in humans structurally, and functional consequences are similar. In both species, valvular interstitial cells (VICs) in affected valves exhibit phenotype consistent with activated myofibroblasts with increased alpha-smooth muscle actin (αSMA) expression. Using VICs collected from normal and MVP-affected valves of dogs, we analyzed the miRNA expression profile of the cells and their associated small extracellular vesicles (sEV) using RNA sequencing to understand the role of non-coding RNAs and sEV in MVP pathogenesis.
MeSH term(s)	Adult ; Animals ; Dogs ; Humans ; Aortic Valve/pathology ; Aortic Valve Stenosis ; Cells, Cultured ; MicroRNAs/genetics ; Mitral Valve Prolapse/metabolism ; Mitral Valve Prolapse/pathology ; Actins/metabolism ; Kruppel-Like Factor 4/metabolism
Chemical Substances	MicroRNAs ; MIRN145 microRNA, human ; Actins ; Kruppel-Like Factor 4
Language	English
Publishing date	2024-01-25
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms25031468
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: The effects of two intramuscular sedation protocols on echocardiographic variables in cats following sedation and blood donation.

Reader, Rebecca C / Yang, Vicky K / Babyak, Jonathan M / Abelson, Amanda L

Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)

2021 Volume 31, Issue 2, Page(s) 256–262

Abstract: Objective: To compare effects of 2 IM sedation protocols, alfaxalone-butorphanol (AB) versus dexmedetomidine-butorphanol (DB), on echocardiographic (ECHO) variables in cats following sedation and blood donation.: Design: Experimental randomized, ... ...

Abstract	Objective: To compare effects of 2 IM sedation protocols, alfaxalone-butorphanol (AB) versus dexmedetomidine-butorphanol (DB), on echocardiographic (ECHO) variables in cats following sedation and blood donation. Design: Experimental randomized, blinded crossover study. Setting: University teaching hospital. Animals: Eleven client-owned healthy cats. Interventions: Cats received a baseline ECHO without sedation prior to their first donation. Cats were sedated intramuscularly with AB (alfaxalone, 2 mg/kg, and butorphanol, 0.2 mg/kg) for 1 donation and DB (dexmedetomidine, 10 μg/kg, and butorphanol 0.2, mg/kg) for another, with a minimum 6 weeks between donations. A post-sedation, post-donation ECHO was performed after each blood donation. Measurements and main results: Eight cats completed the study. Compared to baseline, DB combined with blood donation decreased heart rate (-84/min; P < 0.0001), fractional shortening (-16.5%; P < 0.0001), ejection fraction (-21.0%; P = 0.0002), and cardiac output (-292 mL/min, P = 0.0001); AB combined with blood donation increased heart rate (+45/min; P = 0.0003) and decreased left ventricular end diastolic volume (-1.57 mL; P < 0.0001). Compared to AB, DB decreased heart rate (-129/min; P < 0.0001) and fractional shortening (-21.6%; P < 0.0001) and increased left ventricular end-systolic (+1.14 mL; P = 0.0004) and diastolic volumes (+1.93 mL; P < 0.0002). Cats administered DB had a significant increase in regurgitant flow across mitral, aortic, and pulmonic valves following blood donation (P < 0.05). One cat administered DB developed spontaneous echo contrast in the left ventricle following donation. Conclusions and clinical relevance: Compared to AB, DB had more pronounced effects on ECHO variables in cats following IM sedation and blood donation. Due to its minimal impact on ECHO variables, AB may be a more desirable sedation protocol in this population of cats.
MeSH term(s)	Anesthesia/veterinary ; Animals ; Blood Donors ; Butorphanol/pharmacology ; Cats/physiology ; Conscious Sedation/veterinary ; Cross-Over Studies ; Dexmedetomidine/pharmacology ; Echocardiography/veterinary ; Female ; Heart Rate/drug effects ; Heart Ventricles/diagnostic imaging ; Heart Ventricles/drug effects ; Hypnotics and Sedatives/administration & dosage ; Hypnotics and Sedatives/pharmacology ; Injections, Intramuscular/veterinary ; Male ; Pregnanediones/pharmacology
Chemical Substances	Hypnotics and Sedatives ; Pregnanediones ; Dexmedetomidine (67VB76HONO) ; alphaxalone (BD07M97B2A) ; Butorphanol (QV897JC36D)
Language	English
Publishing date	2021-03-13
Publishing country	United States
Document type	Journal Article ; Randomized Controlled Trial, Veterinary
ZDB-ID	2077212-9
ISSN	1476-4431 ; 1479-3261
ISSN (online)	1476-4431
ISSN	1479-3261
DOI	10.1111/vec.13058
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications.

Camarda, Nicholas / Travers, Richard / Yang, Vicky K / London, Cheryl / Jaffe, Iris Z

Current oncology reports

2022 Volume 24, Issue 4, Page(s) 463–474

Abstract: Purpose of review: While vascular endothelial growth factor receptor inhibitors (VEGFRis) have dramatically improved cancer survival, these drugs cause hypertension in a majority of patients. This side effect is often dose limiting and increases ... ...

Abstract	Purpose of review: While vascular endothelial growth factor receptor inhibitors (VEGFRis) have dramatically improved cancer survival, these drugs cause hypertension in a majority of patients. This side effect is often dose limiting and increases cardiovascular mortality in cancer survivors. This review summarizes recent advances in our understanding of the molecular mechanisms and clinical findings that impact management of VEGFRi-induced hypertension. Recent findings: Recent studies define new connections between endothelial dysfunction and VEGFRi-induced hypertension, including the balance between nitric oxide, oxidative stress, endothelin signaling, and prostaglandins and the potential role of microparticles, vascular smooth muscle cells, vascular stiffness, and microvessel rarefaction. Data implicating genetic polymorphisms that might identify patients at risk for VEGFRi-induced hypertension and the growing body of literature associating VEGFRi-induced hypertension with antitumor efficacy are reviewed. These recent advances have implications for the future of cardio-oncology clinics and the management of VEGFRi-induced hypertension.
MeSH term(s)	Angiogenesis Inhibitors/adverse effects ; Humans ; Hypertension/chemically induced ; Hypertension/drug therapy ; Receptors, Vascular Endothelial Growth Factor ; Signal Transduction ; Vascular Endothelial Growth Factor A
Chemical Substances	Angiogenesis Inhibitors ; Vascular Endothelial Growth Factor A ; Receptors, Vascular Endothelial Growth Factor (EC 2.7.10.1)
Language	English
Publishing date	2022-02-18
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Review
ZDB-ID	2057359-5
ISSN	1534-6269 ; 1523-3790
ISSN (online)	1534-6269
ISSN	1523-3790
DOI	10.1007/s11912-022-01224-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5521: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Intravenous administration of allogeneic Wharton jelly-derived mesenchymal stem cells for treatment of dogs with congestive heart failure secondary to myxomatous mitral valve disease

Yang, Vicky K. / Meola, Dawn M. / Davis, Airiel / Barton, Bruce / Hoffman, Andrew M.

American journal of veterinary research. 2021 June, v. 82, no. 6

2021

Abstract: OBJECTIVE To evaluate whether mesenchymal stem cells (MSCs) can be safely administered IV to dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD) to improve cardiac function and prolong survival time. ANIMALS 10 ... ...

Abstract	OBJECTIVE To evaluate whether mesenchymal stem cells (MSCs) can be safely administered IV to dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD) to improve cardiac function and prolong survival time. ANIMALS 10 client-owned dogs with CHF secondary to MMVD. PROCEDURES Dogs with an initial episode of CHF secondary to MMVD were enrolled in a double-blind, placebo-controlled clinical trial. Five dogs in the MSC group received allogeneic Wharton jelly-derived MSCs (2 × 106 cells/kg, IV), and 5 dogs in the placebo group received a 1% solution of autologous serum (IV) for 3 injections 3 weeks apart. Cell-release criteria included trilineage differentiation, expression of CD44 and CD90 and not CD34 and major histocompatability complex class II, normal karyotype, and absence of contamination by pathogenic microorganisms. Patients were followed for 6 months or until death or euthanasia. Echocardiographic data, ECG findings, serum cardiac biomarker concentrations, CBC, and serum biochemical analysis results were obtained prior to and 4 hours after the first injection and every 3 months after the final injection. RESULTS Lymphocyte and eosinophil counts decreased significantly 4 hours after injection, and monocytes decreased significantly only in dogs that received an MSC injection. No significant differences were seen in the echocardiographic variables, ECG results, serum cardiac biomarker concentrations, survival time, and time to first diuretic drug dosage escalation between the 2 groups. CONCLUSIONS AND CLINICAL RELEVANCE This study showed that MSCs can be easily collected from canine Wharton jelly as an allogeneic source of MSCs and can be safely delivered IV to dogs with CHF secondary to MMVD.
Keywords	biomarkers ; blood serum ; cardiac output ; clinical trials ; death ; dogs ; drugs ; echocardiography ; euthanasia ; heart failure ; intravenous injection ; karyotyping ; mesenchymal stromal cells ; monocytes ; placebos ; veterinary medicine
Language	English
Dates of publication	2021-06
Size	p. 487-493.
Publishing place	American Veterinary Medical Association
Document type	Article
ZDB-ID	390796-x
ISSN	1943-5681 ; 0002-9645
ISSN (online)	1943-5681
ISSN	0002-9645
DOI	10.2460/ajvr.82.6.487
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Bonn / Germany

Z 3312: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Intravenous administration of allogeneic Wharton jelly-derived mesenchymal stem cells for treatment of dogs with congestive heart failure secondary to myxomatous mitral valve disease.

Yang, Vicky K / Meola, Dawn M / Davis, Airiel / Barton, Bruce / Hoffman, Andrew M

American journal of veterinary research

2021 Volume 82, Issue 6, Page(s) 487–493

Abstract: Objective: To evaluate whether mesenchymal stem cells (MSCs) can be safely administered IV to dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD) to improve cardiac function and prolong survival time.: Animals!# ...

Abstract	Objective: To evaluate whether mesenchymal stem cells (MSCs) can be safely administered IV to dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD) to improve cardiac function and prolong survival time. Animals: 10 client-owned dogs with CHF secondary to MMVD. Procedures: Dogs with an initial episode of CHF secondary to MMVD were enrolled in a double-blind, placebo-controlled clinical trial. Five dogs in the MSC group received allogeneic Wharton jelly-derived MSCs (2 × 10 Results: Lymphocyte and eosinophil counts decreased significantly 4 hours after injection, and monocytes decreased significantly only in dogs that received an MSC injection. No significant differences were seen in the echocardiographic variables, ECG results, serum cardiac biomarker concentrations, survival time, and time to first diuretic drug dosage escalation between the 2 groups. Conclusions and clinical relevance: This study showed that MSCs can be easily collected from canine Wharton jelly as an allogeneic source of MSCs and can be safely delivered IV to dogs with CHF secondary to MMVD.
MeSH term(s)	Administration, Intravenous/veterinary ; Animals ; Dog Diseases/drug therapy ; Dogs ; Heart Failure/therapy ; Heart Failure/veterinary ; Hematopoietic Stem Cell Transplantation/veterinary ; Mesenchymal Stem Cells ; Mitral Valve ; Pharmaceutical Preparations ; Wharton Jelly
Chemical Substances	Pharmaceutical Preparations
Language	English
Publishing date	2021-05-25
Publishing country	United States
Document type	Journal Article ; Randomized Controlled Trial, Veterinary
ZDB-ID	390796-x
ISSN	1943-5681 ; 0002-9645
ISSN (online)	1943-5681
ISSN	0002-9645
DOI	10.2460/ajvr.82.6.487
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 422: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Using cultured canine cardiac slices to model the autophagic flux with doxorubicin.

Boukhalfa, Asma / Robinson, Sally R / Meola, Dawn M / Robinson, Nicholas A / Ling, Lauren A / LaMastro, Joey N / Upshaw, Jenica N / Pulakat, Lakshmi / Jaffe, Iris Z / London, Cheryl A / Chen, Howard H / Yang, Vicky K

PloS one

2023 Volume 18, Issue 3, Page(s) e0282859

Abstract: Chemotherapy-induced impairment of autophagy is implicated in cardiac toxicity induced by anti-cancer drugs. Imperfect translation from rodent models and lack of in vitro models of toxicity has limited investigation of autophagic flux dysregulation, ... ...

Abstract	Chemotherapy-induced impairment of autophagy is implicated in cardiac toxicity induced by anti-cancer drugs. Imperfect translation from rodent models and lack of in vitro models of toxicity has limited investigation of autophagic flux dysregulation, preventing design of novel cardioprotective strategies based on autophagy control. Development of an adult heart tissue culture technique from a translational model will improve investigation of cardiac toxicity. We aimed to optimize a canine cardiac slice culture system for exploration of cancer therapy impact on intact cardiac tissue, creating a translatable model that maintains autophagy in culture and is amenable to autophagy modulation. Canine cardiac tissue slices (350 μm) were generated from left ventricular free wall collected from euthanized client-owned dogs (n = 7) free of cardiovascular disease at the Foster Hospital for Small Animals at Tufts University. Cell viability and apoptosis were quantified with MTT assay and TUNEL staining. Cardiac slices were challenged with doxorubicin and an autophagy activator (rapamycin) or inhibitor (chloroquine). Autophagic flux components (LC3, p62) were quantified by western blot. Cardiac slices retained high cell viability for >7 days in culture and basal levels of autophagic markers remained unchanged. Doxorubicin treatment resulted in perturbation of the autophagic flux and cell death, while rapamycin co-treatment restored normal autophagic flux and maintained cell survival. We developed an adult canine cardiac slice culture system appropriate for studying the effects of autophagic flux that may be applicable to drug toxicity evaluations.
MeSH term(s)	Animals ; Dogs ; Myocytes, Cardiac/metabolism ; Cardiotoxicity/metabolism ; Autophagy ; Doxorubicin/pharmacology ; Doxorubicin/metabolism ; Sirolimus/pharmacology
Chemical Substances	Doxorubicin (80168379AG) ; Sirolimus (W36ZG6FT64)
Language	English
Publishing date	2023-03-16
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0282859
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Clinical findings and survival time in dogs with advanced heart failure.

Beaumier, Amelie / Rush, John E / Yang, Vicky K / Freeman, Lisa M

Journal of veterinary internal medicine

2018 Volume 32, Issue 3, Page(s) 944–950

Abstract: Background: Dogs with advanced heart failure are a clinical challenge for veterinarians but there are no studies reporting clinical features and outcome of this population.: Hypothesis/objectives: To describe clinical findings and outcome of dogs ... ...

Abstract	Background: Dogs with advanced heart failure are a clinical challenge for veterinarians but there are no studies reporting clinical features and outcome of this population. Hypothesis/objectives: To describe clinical findings and outcome of dogs with advanced heart failure caused by degenerative mitral valve disease (DMVD). Animals: Fifty-four dogs with advanced heart failure because of DMVD. Methods: For study purposes, advanced heart failure was defined as recurrence of congestive heart failure signs despite receiving the initially prescribed dose of pimobendan, angiotensin-converting-enzyme inhibitor (ACEI), and furosemide >4 mg/kg/day. Data were collected for the time of diagnosis of Stage C heart failure and time of diagnosis of advanced heart failure. Date of death was recorded. Results: At the diagnosis of advanced heart failure, doses of pimobendan (n = 30), furosemide (n = 28), ACEI (n = 13), and spironolactone (n = 4) were increased, with ≥1 new medications added in most dogs. After initial diagnosis of advanced heart failure, 38 (70%) dogs had additional medications adjustments (median = 2 [range, 0-27]), with the final total medication number ranging from 2-10 (median = 5). Median survival time after diagnosis of advanced heart failure was 281 days (range, 3-885 days). Dogs receiving a furosemide dose >6.70 mg/kg/day had significantly longer median survival times (402 days [range, 3-885 days] versus 129 days [range 9-853 days]; P = .017). Conclusions and clinical importance: Dogs with advanced heart failure can have relatively long survival times. Higher furosemide dose and non-hospitalization were associated with longer survival.
MeSH term(s)	Animals ; Cardiotonic Agents/therapeutic use ; Dog Diseases/drug therapy ; Dog Diseases/mortality ; Dogs ; Female ; Furosemide/therapeutic use ; Heart Failure/drug therapy ; Heart Failure/etiology ; Heart Failure/mortality ; Heart Failure/veterinary ; Male ; Mitral Valve Insufficiency/complications ; Mitral Valve Insufficiency/mortality ; Mitral Valve Insufficiency/veterinary ; Pyridazines/therapeutic use ; Spironolactone/therapeutic use ; Survival Analysis ; Treatment Outcome
Chemical Substances	Cardiotonic Agents ; Pyridazines ; Spironolactone (27O7W4T232) ; pimobendan (34AP3BBP9T) ; Furosemide (7LXU5N7ZO5)
Language	English
Publishing date	2018-04-10
Publishing country	United States
Document type	Journal Article
ZDB-ID	92798-3
ISSN	1939-1676 ; 0891-6640
ISSN (online)	1939-1676
ISSN	0891-6640
DOI	10.1111/jvim.15126
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4095: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Retrospective study of dilated cardiomyopathy in dogs

Freid, Kimberly J / Freeman, Lisa M / Rush, John E / Cunningham, Suzanne M / Davis, Megan S / Karlin, Emily T / Yang, Vicky K

Journal of veterinary internal medicine. 2021 Jan., v. 35, no. 1

2021

Abstract: BACKGROUND: The United States Food and Drug Administration is investigating possible diet‐associated dilated cardiomyopathy (DCM) in dogs and cats. OBJECTIVES: To retrospectively review DCM cases for signalment, diet information, echocardiographic ... ...

Abstract	BACKGROUND: The United States Food and Drug Administration is investigating possible diet‐associated dilated cardiomyopathy (DCM) in dogs and cats. OBJECTIVES: To retrospectively review DCM cases for signalment, diet information, echocardiographic changes, and survival. ANIMALS: Client‐owned dogs (n = 71). METHODS: Medical records of dogs diagnosed with DCM between January 1, 2014 and September 30, 2018 were reviewed. Dogs were grouped into “traditional” or “nontraditional” diet categories and whether or not diet was changed after diagnosis. RESULTS: For dogs eating nontraditional diets, those that had their diets changed had a larger percentage decrease in normalized systolic left ventricular internal dimension (P = .03) and left atrial:aorta ratio (P < .001) compared to those that did not have their diets changed. Survival time was significantly longer for dogs with DCM eating nontraditional diets that had their diets changed (median survival, 337 days; range, 9‐1307 days) compared to dogs eating nontraditional diets that did not have their diets changed (median survival, 215 days; range, 1‐852 days; P = .002). CONCLUSIONS AND CLINICAL IMPORTANCE: Dogs with DCM eating nontraditional diets can experience improvement in cardiac function after diet change but additional research is needed to examine possible associations between diet and DCM.
Keywords	Food and Drug Administration ; cardiac output ; cardiomyopathy ; diet ; echocardiography ; nutrition information ; retrospective studies ; veterinary medicine
Language	English
Dates of publication	2021-01
Size	p. 58-67.
Publishing place	John Wiley & Sons, Inc.
Document type	Article
Note	NAL-AP-2-clean ; JOURNAL ARTICLE
ZDB-ID	92798-3
ISSN	1939-1676 ; 0891-6640
ISSN (online)	1939-1676
ISSN	0891-6640
DOI	10.1111/jvim.15972
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 4095: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Clinical findings and survival time in dogs with advanced heart failure

Beaumier, Amelie / Rush, John E / Yang, Vicky K / Freeman, Lisa M

Journal of veterinary internal medicine. 2018 May, v. 32, no. 3

2018

Abstract: BACKGROUND: Dogs with advanced heart failure are a clinical challenge for veterinarians but there are no studies reporting clinical features and outcome of this population. HYPOTHESIS/OBJECTIVES: To describe clinical findings and outcome of dogs with ... ...

Abstract	BACKGROUND: Dogs with advanced heart failure are a clinical challenge for veterinarians but there are no studies reporting clinical features and outcome of this population. HYPOTHESIS/OBJECTIVES: To describe clinical findings and outcome of dogs with advanced heart failure caused by degenerative mitral valve disease (DMVD). ANIMALS: Fifty‐four dogs with advanced heart failure because of DMVD. METHODS: For study purposes, advanced heart failure was defined as recurrence of congestive heart failure signs despite receiving the initially prescribed dose of pimobendan, angiotensin‐converting‐enzyme inhibitor (ACEI), and furosemide >4 mg/kg/day. Data were collected for the time of diagnosis of Stage C heart failure and time of diagnosis of advanced heart failure. Date of death was recorded. RESULTS: At the diagnosis of advanced heart failure, doses of pimobendan (n = 30), furosemide (n = 28), ACEI (n = 13), and spironolactone (n = 4) were increased, with ≥1 new medications added in most dogs. After initial diagnosis of advanced heart failure, 38 (70%) dogs had additional medications adjustments (median = 2 [range, 0‐27]), with the final total medication number ranging from 2‐10 (median = 5). Median survival time after diagnosis of advanced heart failure was 281 days (range, 3‐885 days). Dogs receiving a furosemide dose >6.70 mg/kg/day had significantly longer median survival times (402 days [range, 3‐885 days] versus 129 days [range 9‐853 days]; P = .017). CONCLUSIONS AND CLINICAL IMPORTANCE: Dogs with advanced heart failure can have relatively long survival times. Higher furosemide dose and non‐hospitalization were associated with longer survival.
Keywords	angiotensin-converting enzyme inhibitors ; death ; dogs ; drug therapy ; furosemide ; heart failure ; spironolactone ; veterinarians
Language	English
Dates of publication	2018-05
Size	p. 944-950.
Publishing place	John Wiley & Sons, Ltd
Document type	Article
Note	JOURNAL ARTICLE
ZDB-ID	92798-3
ISSN	1939-1676 ; 0891-6640
ISSN (online)	1939-1676
ISSN	0891-6640
DOI	10.1111/jvim.15126
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 4095: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Retrospective study of dilated cardiomyopathy in dogs.

Freid, Kimberly J / Freeman, Lisa M / Rush, John E / Cunningham, Suzanne M / Davis, Megan S / Karlin, Emily T / Yang, Vicky K

Journal of veterinary internal medicine

2020 Volume 35, Issue 1, Page(s) 58–67

Abstract: Background: The United States Food and Drug Administration is investigating possible diet-associated dilated cardiomyopathy (DCM) in dogs and cats.: Objectives: To retrospectively review DCM cases for signalment, diet information, echocardiographic ... ...

Abstract	Background: The United States Food and Drug Administration is investigating possible diet-associated dilated cardiomyopathy (DCM) in dogs and cats. Objectives: To retrospectively review DCM cases for signalment, diet information, echocardiographic changes, and survival. Animals: Client-owned dogs (n = 71). Methods: Medical records of dogs diagnosed with DCM between January 1, 2014 and September 30, 2018 were reviewed. Dogs were grouped into "traditional" or "nontraditional" diet categories and whether or not diet was changed after diagnosis. Results: For dogs eating nontraditional diets, those that had their diets changed had a larger percentage decrease in normalized systolic left ventricular internal dimension (P = .03) and left atrial:aorta ratio (P < .001) compared to those that did not have their diets changed. Survival time was significantly longer for dogs with DCM eating nontraditional diets that had their diets changed (median survival, 337 days; range, 9-1307 days) compared to dogs eating nontraditional diets that did not have their diets changed (median survival, 215 days; range, 1-852 days; P = .002). Conclusions and clinical importance: Dogs with DCM eating nontraditional diets can experience improvement in cardiac function after diet change but additional research is needed to examine possible associations between diet and DCM.
MeSH term(s)	Animals ; Cardiomyopathy, Dilated/veterinary ; Cat Diseases ; Cats ; Dog Diseases/etiology ; Dogs ; Echocardiography/veterinary ; Retrospective Studies
Language	English
Publishing date	2020-12-21
Publishing country	United States
Document type	Journal Article
ZDB-ID	92798-3
ISSN	1939-1676 ; 0891-6640
ISSN (online)	1939-1676
ISSN	0891-6640
DOI	10.1111/jvim.15972
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4095: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito